TLSA stock forecast, quote, news & analysis
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases... Show more
Why Tiziana Life Sciences (TLSA) Stock Is Down -40.5% in the Last 30 Days
Key Takeaways
- Tiziana Life Sciences (TLSA) shares have declined roughly 40.5% over the trailing 30 days, extending a longer slide for the clinical-stage biotech.
- The drop came despite a Nov. 2 announcement that the Phase 2a INFORM-MS trial of intranasal foralumab met its dual primary endpoints in non-active secondary progressive multiple sclerosis (na-SPMS).
- The 50 microgram dose significantly reduced microglial activation versus placebo (p=0.0168), but the exploratory 100 microgram dose did not reach statistical significance on PET imaging.
- "Sell-the-news" profit-taking, a small 48-patient trial, and the capital requirements typical of a pre-revenue biotech have weighed on investor sentiment.
- Over the trailing quarter, TLSA is down about 35.8%, trading near the low end of its 52-week range and down more than 50% year to date.
- For deeper context on valuation and upcoming catalysts, review TLSA's Price Targets, Earnings, and Forecast.
- Explore Tickeron's Trending AI Robots to see how AI-driven trading strategies are positioned across the market.
Tiziana Life Sciences (TLSA) Company Overview and Market Position
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing immunomodulation therapies for neuroinflammatory and neurodegenerative diseases. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody being studied in non-active secondary progressive multiple sclerosis (na-SPMS), Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company's core differentiator is its intranasal delivery technology, which is designed to stimulate regulatory T cells and reduce microglial-driven neuroinflammation while potentially offering a more tolerable profile than intravenous dosing. Because Tiziana has no approved products and generates no meaningful product revenue, the stock is followed primarily for its clinical data readouts, regulatory milestones, and the substantial unmet need in progressive multiple sclerosis.
Tiziana Life Sciences (TLSA) Stock Price Performance: Last 30 Days vs. Quarter
TLSA has fallen approximately 40.5% over the last 30 days. The shares closed near $1.09 about a month earlier and have since declined to around $0.65, reflecting sustained selling pressure through late October and early November. The stock hit an intraday high above $1.24 in early October before rolling over, and it has recently traded near the low end of its 52-week range, which spans roughly $0.62 to $1.95.
The quarterly trend tells a similar story. Three months ago, TLSA closed near $1.01, putting the trailing-quarter decline at about 35.8%. Within that period, the stock first drifted higher into the anticipated INFORM-MS data readout, then reversed sharply once topline results were released, giving back those gains and more. The result is a clear downward trend across both the one-month and three-month timeframes.
What Drove TLSA Stock Price in the Last 30 Days
The defining event of the past month was the Nov. 2 release of topline results from the Phase 2a INFORM-MS trial. Tiziana reported that intranasal foralumab met its dual primary endpoints of safety/tolerability and a statistically significant reduction in microglial activation for the 50 microgram dose versus placebo (p=0.0168), alongside improvements in fatigue scores. Yet the stock declined on and after the announcement, a classic "sell-the-news" reaction following the run-up into the readout.
Several factors tempered investor enthusiasm despite the positive headline data. The trial enrolled only 48 patients, and the exploratory 100 microgram dose did not achieve statistical significance on PET imaging, leaving questions about the dose-response relationship. As a pre-revenue company, Tiziana also carries ongoing capital requirements, and small-cap biotechnology names broadly faced risk-off sentiment. These dynamics outweighed the favorable topline data in the short term, pushing shares to multi-month lows even as the company hosted a key opinion leader call and presented at BIO-Europe 2026.
What Drove TLSA Stock Performance Over the Last Quarter
The quarterly decline reflects a broader reassessment of Tiziana's risk-reward profile. Early in the period, the company reported a steady stream of clinical updates, including reduced brain inflammation in a third MSA patient treated with intranasal foralumab, first participant dosing in the ALS BANYAN trial, the filing for orphan drug designation in MSA, and the signing of a memorandum of understanding with King Abdullah International Medical Research Center. The CEO also disclosed an insider share purchase in August, a signal some investors read as confidence in the pipeline.
Those catalysts supported the stock into the data readout, but the subsequent reversal suggests the market had already priced in a favorable INFORM-MS outcome. With the initial data now public, attention has shifted to the longer path ahead — confirmatory trials, regulatory discussions, and the financing needed to fund late-stage development — which has kept pressure on the shares through the quarter.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that analyze thousands of tickers, but only the top-performing and most relevant strategies are surfaced in its curated Trending AI Robots section. These bots vary considerably in strategy, timeframe, and performance metrics, allowing users to compare approaches rather than rely on a single model. The section is designed to help traders and investors identify automated strategies that are currently generating notable results across the market. Those interested in a data-driven, systematic perspective on names like TLSA can explore the available robots to see how different models are positioned.
TLSA Stock Forecast Drivers: What Investors Should Watch Next
The next phase of Tiziana's story hinges on its ability to translate the INFORM-MS results into a viable regulatory path. Investors should watch for the full data presentation at an upcoming scientific meeting and the company's discussions with the FDA regarding next steps for intranasal foralumab in na-SPMS. Additional Phase 2 readouts in Alzheimer's disease, ALS, and MSA represent further potential catalysts, while partnership or business development announcements could alter the funding outlook. As a clinical-stage company, Tiziana's cash runway and any future equity financing will remain central considerations. Broader small-cap biotechnology sentiment and interest-rate expectations may also influence how the stock trades around these milestones.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TLSA turns negative, indicating new downward trend
TLSA saw its Momentum Indicator move below the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 90 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TLSA turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 49 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TLSA moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TLSA crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for TLSA entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
TLSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.834) is normal, around the industry mean (3.498). P/E Ratio (-4.052) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. TLSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology